Safety and efficacy of first-line Osimertinib therapy including the frequency of drug-induced lung disease

Safety and efficacy of first-line Osimertinib therapy including the frequency of drug-induced lung disease - Safety and efficacy of first-line Osimertinib therapy including the frequency of drug-induced lung disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044863

Enrollment

160

Registered

2021-07-19

Start date

2021-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients for whom information on medical treatment and prognosis can be obtained from medical records. 2.Patients with a confirmed diagnosis of non-small cell lung cancer and positive EGFR mutation who received Osimertinib as first-line therapy 3.Patients who are 20 years old or older.

Exclusion criteria

Exclusion criteria: 1.Patients who have requested not to participate in this study based on the published information. 2.Patients who are currently participating or will participate in clinical research involving interventions related to pharmacotherapy. 3.Other patients who are judged ineligible by the principal investigator.

Design outcomes

Primary

Measure	Time frame
the frequency of drug-induced lung disease	—

Countries

Japan

Contacts

Public ContactChihiro Mimura

Kobe University Hospital Division of Respiratory Medicine

f9s5m1s3@gmail.com078-382-5660

Outcome results